A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
A Phase 1, Dose-escalation, Blinded Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children (9 to <18 Years of Age)
The purpose of this study is to evaluate safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy children (9 to <18 years of age).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Moderna WeCare Team
- Phone Number: +1-866-663-3762
- Email: WeCareClinicalTrials@modernatx.com
Study Locations
-
-
California
-
Modesto, California, United States, 95355
- Recruiting
- Paradigm Clinical Research Centers, LLC
-
-
Colorado
-
Aurora, Colorado, United States, 80012
- Recruiting
- Paradigm Clinical Research Centers, LLC
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55402
- Recruiting
- Clinical Research Institute, Inc
-
-
Ohio
-
South Euclid, Ohio, United States, 44121
- Recruiting
- Senders Pediatrics
-
-
Texas
-
Houston, Texas, United States, 77055
- Recruiting
- West Houston Clinical Research Service
-
-
Virginia
-
Richmond, Virginia, United States, 23226
- Recruiting
- Clinical Research Partners, LLC.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 9 to <18 years of age inclusive, at the time of signing the informed consent/assent.
- In the Investigator's opinion, the participants/participant's parent(s)/legally authorized representative (LAR(s)) demonstrate adequate understanding of the study requirements and are willing and physically able to comply with protocol mandated follow-up, including all procedures.
- For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, and agreement to continue adequate contraception through 90 days following vaccine administration.
Exclusion Criteria:
- History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic; influenza vaccine; or components of influenza vaccine, including egg protein.
- Acutely ill or febrile (temperature ≥38.0 degrees Celsius (℃) [100.4 degrees Fahrenheit [°F]) within 72 hours prior to or at the Screening Visit or Day 1. Participants who are acutely ill or febrile may be scheduled for a separate dosing visit within the window specified for Screening.
- History of a diagnosis or condition not specifically listed as exclusionary that, in the judgment of the Investigator, is clinically unstable, potentially affects participant safety, the assessment of study endpoints, the assessment of immune response, or adherence to study procedures.
- Any prior systemic immunosuppressants, immunomodulators (for example, methotrexate, cyclosporine), or long-acting biological therapies that may affect immune responses (for example, dupilumab, omalizumab). Short courses (<7 days) of oral corticosteroids are allowed if completed at least 3 months prior to Day 1. Inhaled, nasal, topical steroids, and subcutaneous injected allergy immunotherapy (allergy shots) are allowed.
- Received systemic immunoglobulins or blood products within 90 days prior to the Screening Visit or plans to receive them during the study.
- Received any nonstudy vaccine authorized or approved by local health agency within 14 days (28 days for live vaccines and mRNA vaccines) prior to Day 1 (inclusive) or plans to receive any nonstudy vaccine within 28 days post study vaccine administration.
- Donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products within 28 days post study vaccine administration.
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: mRNA-1010 Low Dose
Participants will receive a single low dose of mRNA-1010 by intramuscular (IM) injection on Day 1. |
Suspension for injection
Other Names:
|
|
Experimental: mRNA-1010 Full Dose
Participants will receive a single full dose of mRNA-1010 by intramuscular (IM) injection on Day 1. |
Suspension for injection
Other Names:
|
|
Active Comparator: Fluarix Trivalent
Participants will receive a single dose of Fluarix Trivalent by IM injection on Day 1. |
Suspension for injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay
Time Frame: Day 29
|
Day 29
|
|
|
Percentage of Participants With HAI Titer ≥ 1:40 at Day 29
Time Frame: Day 29
|
Day 29
|
|
|
Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Time Frame: Up to Day 7 (7 days after vaccination)
|
Up to Day 7 (7 days after vaccination)
|
|
|
Number of Participants with Unsolicited Adverse Events (AEs)
Time Frame: Up to Day 28 (28 days after vaccination)
|
Up to Day 28 (28 days after vaccination)
|
|
|
Number of Participants with AEs Leading to Discontinuation, Serious Adverse Events (SAEs), or Adverse Events of Special Interest (AESI)
Time Frame: Day 1 through Day 365
|
Day 1 through Day 365
|
|
|
Number of Participants with Medically Attended AEs (MAAEs)
Time Frame: Day 1 through Day 181
|
Day 1 through Day 181
|
|
|
Percentage of Participants Reaching Seroconversion, as Measured by HAI Assay
Time Frame: Day 29
|
Seroconversion is defined as either a pre-vaccination HAI titer <1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HAI antibody titer. |
Day 29
|
|
Geometric Mean Fold Rise (GMFR) of Anti-HA antibodies, as Measured by HAI Assays
Time Frame: Day 29
|
Day 29
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- mRNA-1010-P102
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.